Compare Ascendis Pharma A/S (ASND) vs Comfort Systems USA Inc (FIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Comfort Systems USA Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Comfort Systems USA Inc trades at $1,710.55 (market cap $61.82B). The key difference: Comfort Systems USA Inc is far larger — about 3.5× Ascendis Pharma A/S's market cap, and Comfort Systems USA Inc pays a 0.15% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | FIX | |
|---|---|---|
Market Cap | $17.74B | $61.82B |
Sector | Health | Technology |
52-Week High | $277.18 | $2.07K |
52-Week Low | $163.32 | $532.14 |
Enterprise Value | $18.11B | $61.11B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Comfort Systems USA (FIX) trades at $1,756.09, down 1.42% on the day, amid a bearish technical signal. The stock exhibits strong fundamentals with consistent earnings beats, robust revenue growth to $10.1B in 2026, and high profitability margins. Recent news highlights expansion in modular capabilities and leadership transitions, while analyst consensus remains bullish with a $2,100 price target.
Outlook is positive driven by AI infrastructure demand and a record backlog, though premium valuation multiples pose a risk. Execution of growth initiatives and macroeconomic conditions are key watchpoints for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →
